首页 > 最新文献

European journal of gynaecological oncology最新文献

英文 中文
Conservative surgical treatment of uterine fibroids in women of childbearing age 育龄妇女子宫肌瘤的保守手术治疗
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.053
Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.
子宫肌瘤是妇科良性肿瘤,已知30 ~ 50岁的女性是子宫肌瘤的高发年龄段。在过去的几年中,越来越多的药物治疗和微创器官保存治疗被设计和实施。然而,目前还没有一种治疗药物表现出理想的治疗效果和低复发率,因此在实际临床治疗中仍然主要采用手术治疗。一般来说,手术治疗已作为保留器官和生育能力的宫腔镜或腹腔镜切除肌瘤。微创手术设备(如宫腔镜、传统的多孔腹腔镜、经脐腹腔镜、经阴道腹腔镜以及机器人辅助腹腔镜)已广泛应用于临床治疗。与传统剖腹手术相比,微创手术设备具有手术微创、高效、安全的特点。随着医疗技术的突飞猛进,介入治疗和射频消融也可用于治疗子宫肌瘤。根据国内外研究进展,本文综述了有生育需求的患者子宫肌瘤治疗的现状、局限性及优势。
{"title":"Conservative surgical treatment of uterine fibroids in women of childbearing age","authors":"","doi":"10.22514/ejgo.2023.053","DOIUrl":"https://doi.org/10.22514/ejgo.2023.053","url":null,"abstract":"Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound-guided thoracic paravertebral nerve block in patients undergoing radical mastectomy 超声引导下胸椎旁神经阻滞在乳房根治术中的应用
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.083
This research aims to investigate the effect of ultrasound-guided continuous thoracic paravertebral nerve block in patients undergoing radical mastectomy. Ninety-six patients who underwent radical mastectomy were equally divided into a study group (administered with a continuous thoracic paravertebral nerve block and general anesthesia) and a control group (given conventional general anesthesia) with a random number table. At T2–T4 (T2: immediate tracheal intubation; T3: at skin incision; T4: at extubation), mean artery pressure (MAP) and hear rate (HR) were significantly lower in the study group (p < 0.05); however, there was no significant difference in blood oxygen saturation (SpO2) between the two groups at different time points. At T2–T4, cortisol (Cor) levels were significantly lower in the study group (p < 0.05). At T0–T2, there was no significant difference in the levels of adrenocorticotropic hormone (ACTH) between the two groups. At T3–T4, the levels of ACTH in the study group were significantly lower (p < 0.05). There were no significant differences in blood pressure between the two groups at any time point. At the moment of discharge from the resuscitation room and 2 hours after surgery, the numerical rating scale (NRS) score in the study group was significantly reduced (p < 0.05). The incidence of adverse reactions in the study group was 10.42%; this was lower than that in the control group (33.33%) (p < 0.05). Finally, the use of fentanyl and propofol, and the frequency of analgesic pump use, were significantly lower in the study group (p < 0.05). Ultrasound-guided thoracic paravertebral nerve block can effectively maintain hemodynamic stability, improve the stress response, reduce postoperative pain, reduce the use of anesthetic drugs, and effectively control the incidence of adverse reactions in patients undergoing radical mastectomy.
本研究旨在探讨超声引导下连续胸椎旁神经阻滞在乳房根治术患者中的应用效果。96例接受根治性乳房切除术的患者平均分为研究组(给予连续胸椎旁神经阻滞和全身麻醉)和对照组(给予常规全身麻醉),采用随机数字表。在T2 - T4 (T2:立即气管插管;T3:皮肤切开;T4:拔管),研究组平均动脉压(MAP)和心率(HR)显著降低(p <两组在不同时间点血氧饱和度(SpO2)差异无统计学意义(p < 0.05)。T2-T4时,研究组皮质醇(Cor)水平显著降低(p <0.05)。T0-T2时,两组促肾上腺皮质激素(ACTH)水平差异无统计学意义。T3-T4时,研究组ACTH水平显著降低(p <0.05)。两组在任何时间点的血压均无显著差异。在复苏室出院时及术后2 h,研究组的数值评定量表(NRS)评分显著降低(p <0.05)。研究组不良反应发生率为10.42%,低于对照组的33.33% (p <0.05)。最后,研究组芬太尼和异丙酚的使用以及镇痛泵的使用频率均显著低于对照组(p <0.05)。超声引导下胸椎旁神经阻滞能有效维持血流动力学稳定,改善应激反应,减轻术后疼痛,减少麻醉药物的使用,有效控制乳房根治术患者不良反应的发生。
{"title":"Ultrasound-guided thoracic paravertebral nerve block in patients undergoing radical mastectomy","authors":"","doi":"10.22514/ejgo.2023.083","DOIUrl":"https://doi.org/10.22514/ejgo.2023.083","url":null,"abstract":"This research aims to investigate the effect of ultrasound-guided continuous thoracic paravertebral nerve block in patients undergoing radical mastectomy. Ninety-six patients who underwent radical mastectomy were equally divided into a study group (administered with a continuous thoracic paravertebral nerve block and general anesthesia) and a control group (given conventional general anesthesia) with a random number table. At T2–T4 (T2: immediate tracheal intubation; T3: at skin incision; T4: at extubation), mean artery pressure (MAP) and hear rate (HR) were significantly lower in the study group (p < 0.05); however, there was no significant difference in blood oxygen saturation (SpO2) between the two groups at different time points. At T2–T4, cortisol (Cor) levels were significantly lower in the study group (p < 0.05). At T0–T2, there was no significant difference in the levels of adrenocorticotropic hormone (ACTH) between the two groups. At T3–T4, the levels of ACTH in the study group were significantly lower (p < 0.05). There were no significant differences in blood pressure between the two groups at any time point. At the moment of discharge from the resuscitation room and 2 hours after surgery, the numerical rating scale (NRS) score in the study group was significantly reduced (p < 0.05). The incidence of adverse reactions in the study group was 10.42%; this was lower than that in the control group (33.33%) (p < 0.05). Finally, the use of fentanyl and propofol, and the frequency of analgesic pump use, were significantly lower in the study group (p < 0.05). Ultrasound-guided thoracic paravertebral nerve block can effectively maintain hemodynamic stability, improve the stress response, reduce postoperative pain, reduce the use of anesthetic drugs, and effectively control the incidence of adverse reactions in patients undergoing radical mastectomy.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of different doses of esketamine on hemodynamic indexes, pain stress indexes, and VAS scores in patients with benign ovarian tumors undergoing laparoscopic resection induced by remifentanil 不同剂量艾氯胺酮对瑞芬太尼致卵巢良性肿瘤腹腔镜切除术患者血流动力学指标、疼痛应激指标及VAS评分的影响
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.082
This study aimed to investigate the effects of different doses of esketamine on hemodynamic indicators, pain stress indicators and Visual Analog Scale (VAS) scores in patients undergoing laparoscopic resection for benign ovarian tumors induced by remifentanil. A total of 110 patients with benign ovarian tumors scheduled for laparoscopic resection between June and December 2023 were included in the study and divided into three groups: Group A (35 cases), Group B (37 cases), and Group C (38 cases), based on their anesthesia regimen. Anesthesia induction for all groups included propofol, remifentanil, and cisatracurium. Group A received an intravenous dose of 0.8 mg/kg esketamine, Group B received 0.6 mg/kg esketamine and Group C did not receive esketamine. The results revealed statistically significant differences in average arterial pressure and heart rate at various time points within each group (p < 0.05), and significant differences were observed in Substance P (SP) and Prostaglandin E2 (PEG2) at three different time points within each group (p < 0.05). VAS scores during and after surgery at 6 and 12 hours significantly differed among the three groups (p < 0.05). There was a significant difference in awakening time among the three groups (p < 0.05). However, there were no statistically significant differences in the incidence of adverse reactions among the three groups (p > 0.05). In conclusion, both 0.6 mg/kg and 0.8 mg/kg doses of esketamine effectively prevented remifentanil-induced hyperalgesia in patients undergoing laparoscopic resection for benign ovarian tumors, significantly reducing patient pain. Notably, the 0.6 mg/kg dose of esketamine demonstrated better hemodynamic stability, promoted patient recovery, and showed superior clinical utility compared to the 0.8 mg/kg dose.
本研究旨在探讨不同剂量艾氯胺酮对瑞芬太尼致卵巢良性肿瘤腹腔镜切除术患者血流动力学指标、疼痛应激指标和视觉模拟评分(VAS)的影响。本研究将于2023年6月至12月行腹腔镜卵巢良性肿瘤切除术的患者共110例纳入研究,根据麻醉方案分为A组(35例)、B组(37例)和C组(38例)。所有组的麻醉诱导包括异丙酚、瑞芬太尼和顺阿曲库铵。A组静脉滴注艾氯胺酮0.8 mg/kg, B组静脉滴注艾氯胺酮0.6 mg/kg, C组不滴注艾氯胺酮。结果显示,各组各时间点平均动脉压和心率差异有统计学意义(p <P物质(SP)和前列腺素E2 (PEG2)在各组内3个不同时间点差异均有统计学意义(P <0.05)。三组患者术后6、12小时VAS评分差异有统计学意义(p <0.05)。三组患者苏醒时间差异有统计学意义(p <0.05)。但三组患者不良反应发生率比较,差异无统计学意义(p >0.05)。综上所述,0.6 mg/kg和0.8 mg/kg剂量的艾氯胺酮均能有效预防腹腔镜卵巢良性肿瘤切除术患者瑞芬太尼致痛觉过敏,显著减轻患者疼痛。值得注意的是,与0.8 mg/kg剂量相比,0.6 mg/kg剂量的艾氯胺酮表现出更好的血流动力学稳定性,促进了患者的康复,并显示出更好的临床效用。
{"title":"Effects of different doses of esketamine on hemodynamic indexes, pain stress indexes, and VAS scores in patients with benign ovarian tumors undergoing laparoscopic resection induced by remifentanil","authors":"","doi":"10.22514/ejgo.2023.082","DOIUrl":"https://doi.org/10.22514/ejgo.2023.082","url":null,"abstract":"This study aimed to investigate the effects of different doses of esketamine on hemodynamic indicators, pain stress indicators and Visual Analog Scale (VAS) scores in patients undergoing laparoscopic resection for benign ovarian tumors induced by remifentanil. A total of 110 patients with benign ovarian tumors scheduled for laparoscopic resection between June and December 2023 were included in the study and divided into three groups: Group A (35 cases), Group B (37 cases), and Group C (38 cases), based on their anesthesia regimen. Anesthesia induction for all groups included propofol, remifentanil, and cisatracurium. Group A received an intravenous dose of 0.8 mg/kg esketamine, Group B received 0.6 mg/kg esketamine and Group C did not receive esketamine. The results revealed statistically significant differences in average arterial pressure and heart rate at various time points within each group (p < 0.05), and significant differences were observed in Substance P (SP) and Prostaglandin E2 (PEG2) at three different time points within each group (p < 0.05). VAS scores during and after surgery at 6 and 12 hours significantly differed among the three groups (p < 0.05). There was a significant difference in awakening time among the three groups (p < 0.05). However, there were no statistically significant differences in the incidence of adverse reactions among the three groups (p > 0.05). In conclusion, both 0.6 mg/kg and 0.8 mg/kg doses of esketamine effectively prevented remifentanil-induced hyperalgesia in patients undergoing laparoscopic resection for benign ovarian tumors, significantly reducing patient pain. Notably, the 0.6 mg/kg dose of esketamine demonstrated better hemodynamic stability, promoted patient recovery, and showed superior clinical utility compared to the 0.8 mg/kg dose.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer 评价卵巢癌患者用计算机断层扫描定量测量的腹水量与化疗毒性的关系
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.078
In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.
在这项研究中,计划探讨腹水和肌肉减少症对3-4期卵巢癌患者治疗毒性、无病生存期(DFS)和疾病特异性生存期(DSS)时间的影响。回顾性研究纳入2012-2019年在某大学附属医院接受治疗并随访的80例晚期卵巢癌患者,利用病历资料,通过计算机断层扫描计算患者的腹水体积和肌肉减少指数,并对其临床病理特征和实验室变量进行分析。腹水患者中位生存期为30.10±2.85个月,无腹水患者中位生存期为54.26±4.16个月(p <0.001)。发现腹水患者的DSS持续时间(风险比(HR): 3.048)、预后营养指数(PNI) & 47.5 (HR: 2.528)、血小板(PLT) & 33.8万(HR: 1.936)、乳酸脱氢酶(LDH)值>320 (HR: 1.624)、白蛋白值<4 (HR: 1.849)均受到负面影响。根据多变量Cox回归分析评估与DSS有显著关系的因素时,腹水的存在被确定为与DSS相关的独立危险因素(p: 0.004)。与没有腹水的患者相比,腹水患者在第一次化疗后发生2级或3级中性粒细胞减少症、贫血和血小板减少症的风险显著增加(p: 0.006)。卵巢癌患者腹水的存在是与化疗毒性和降低生存率相关的危险因素。
{"title":"Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer","authors":"","doi":"10.22514/ejgo.2023.078","DOIUrl":"https://doi.org/10.22514/ejgo.2023.078","url":null,"abstract":"In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor growth inhibition and tumor specific immunity enhancement in endometrial carcinoma by high intensity focused ultrasound 高强度聚焦超声对子宫内膜癌肿瘤生长抑制及肿瘤特异性免疫增强作用的研究
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.085
Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv
子宫内膜癌(EC)是一种常见的上皮恶性肿瘤,约占女性恶性肿瘤总数的8%。发展新的治疗方法对改善子宫内膜癌的预后至关重要。高强度聚焦超声(HIFU)是一种安全、低并发症的肿瘤治疗方法。然而,HIFU治疗EC的报道很少,其机制尚不清楚。本研究检测了HIFU对EC进展的影响。数据证实HIFU对小鼠EC肿瘤生长有抑制作用。HIFU对EC肿瘤的凋亡有抑制作用。下调Treg细胞的产生,增强肿瘤特异性细胞毒性。在体外抑制Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3)通路
{"title":"Tumor growth inhibition and tumor specific immunity enhancement in endometrial carcinoma by high intensity focused ultrasound","authors":"","doi":"10.22514/ejgo.2023.085","DOIUrl":"https://doi.org/10.22514/ejgo.2023.085","url":null,"abstract":"Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GINS2 regulates epithelial mesenchymal transformation and cell cycle in endometrial carcinoma by stimulating ERK/MAPK signaling GINS2通过刺激ERK/MAPK信号传导调节子宫内膜癌上皮间质转化和细胞周期
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.067
Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.
子宫内膜癌是妇科三大肿瘤之一。寻找新的治疗靶点并进一步阐明EC肿瘤发生的分子机制对女性健康具有重要意义。Go-Ichi-Ni-San (GINS)家族包括4个亚基(GINS1-4),在DNA复制和细胞周期中具有特定功能。Cancer Genome Atlas (TCGA)数据显示,GINS2转录水平在子宫内膜癌组织中上调。然而,GINS2在EC进展中的可能作用仍然未知。在此,我们探讨了GINS2在EC中的作用。我们注意到GINS2在EC细胞中过表达。GINS2敲除抑制EC细胞增殖,诱导细胞周期阻滞。我们进一步注意到,GINS2敲低抑制了EC细胞的上皮间充质转化(Epithelial mesenchymal transformation, EMT)。机械上,其下调抑制了细胞外调节蛋白激酶(ERK)/微管相关蛋白激酶(MAPK)途径,从而抑制了EC的进展。因此,GINS2有可能作为EC的治疗靶点。
{"title":"GINS2 regulates epithelial mesenchymal transformation and cell cycle in endometrial carcinoma by stimulating ERK/MAPK signaling","authors":"","doi":"10.22514/ejgo.2023.067","DOIUrl":"https://doi.org/10.22514/ejgo.2023.067","url":null,"abstract":"Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery 基于健康行为改变综合理论的健康教育在宫颈癌根治术后盆底康复中的应用
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.062
To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.
分析基于健康行为改变综合理论的健康教育在宫颈癌根治术后盆底康复中的应用效果。我们招募了130例于2021年2月1日至2022年3月1日在我院接受妇科手术的宫颈癌患者。按随机数字表法将患者分为对照组和观察组,每组65例。对照组接受常规健康教育,观察组接受基于健康行为改变综合理论的健康教育。通过分析PFDI-20(盆底困扰问卷-20)、PFIQ-7(盆底影响问卷-7)、HAMA(汉密尔顿焦虑量表)和HAMD(汉密尔顿抑郁量表)问卷、治疗依从性和护理满意度,比较两组患者干预前后的盆底功能、生活质量和心理状态。干预后,观察组患者PFDI-20评分及总分均低于对照组(p <0.05)。观察组患者PFIQ-7评分及总分均低于对照组(p <0.05)。观察组患者HAMA、HAMD评分均显著低于对照组(p <0.05)。观察组患者的治疗依从性和护理满意率均高于对照组(p <0.05)。基于健康行为改变综合理论的健康教育可提高宫颈癌根治术后盆底肌力,改善患者的生活质量和治疗依从性。此外,该策略可以缓解焦虑和抑郁,提高护理满意度,值得在临床推广应用。
{"title":"Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery","authors":"","doi":"10.22514/ejgo.2023.062","DOIUrl":"https://doi.org/10.22514/ejgo.2023.062","url":null,"abstract":"To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer 钼靶x线检查与多模态MRI在乳腺癌诊断中的价值
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.064
Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.
乳腺癌是最常见的恶性疾病之一,死亡率高,主要影响女性。本研究旨在探讨钼靶x线检查和多模态磁共振成像(MRI)在乳腺癌诊断中的诊断价值。共有60名疑似乳腺癌患者接受了筛查,并纳入了这项研究。所有患者均行钼靶x线及多模态MRI检查,并与病理检查结果进行比较,作为评价不同筛查方法诊断效果的参考标准。钼靶x线检查阳性19例,阴性41例。多模态MRI阳性43例,阴性17例。与钼靶x线相比,多模态MRI具有更高的诊断准确性、特异性和敏感性。进一步分析显示,在45例阳性患者中,1期13例,2期20例,3期9例,4期3例。病理类型分为浸润性导管癌、导管内癌和导管原位癌,分别为25例、6例和14例。与其他两种类型相比,导管内癌表现出更高水平的增强率和信号增强比,峰值时间更短。浸润性导管癌与原位导管癌之间无显著性差异。在乳腺癌的临床诊断中,MRI多模态检查对肿瘤性质和疾病类型的判断更为全面和准确,具有重要的临床价值。
{"title":"Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer","authors":"","doi":"10.22514/ejgo.2023.064","DOIUrl":"https://doi.org/10.22514/ejgo.2023.064","url":null,"abstract":"Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of bone health in breast cancer patients with germline pathogenic 种系致病性乳腺癌患者骨健康的评价
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.090
Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.
由于癌症本身和抗肿瘤治疗的副作用,乳腺癌(BC)患者骨质流失的风险增加。本研究评估了携带生殖系致病变异(pv)的BC幸存者的骨骼健康状况。这是一项回顾性横断面研究。我们确定了2017年2月至2022年12月在Acibadem Altunizade医院乳腺健康中心诊断出BC易感基因pv的165例BC患者。只有80例患者在诊断时接受了双能x线吸收仪(DXA)。患者年龄中位数为44岁。在80例患者中,47% (n = 38)患有BRCA1和BRCA2,而其余53% (n = 42)患有其他pv,我们称之为非brca。21例BRCA患者和6例非BRCA pv患者接受了降低风险的双侧输卵管卵巢切除术(RRBSO) (p <0.001)。在68个月的随访期间,共有53%的患者骨质减少,11%的患者骨质疏松。根据突变类型,在BRCA1和BRCA2患者中,47%出现骨质减少,11%出现骨质疏松症。在非brca患者中,57%有骨质减少,12%有骨质疏松(p >0.05)。在这项研究中,我们发现BRCA和非BRCA突变的患者骨质减少和骨质疏松的发生率相似。这对于非brca突变携带者尤其重要,因为这方面的数据不足。
{"title":"Evaluation of bone health in breast cancer patients with germline pathogenic","authors":"","doi":"10.22514/ejgo.2023.090","DOIUrl":"https://doi.org/10.22514/ejgo.2023.090","url":null,"abstract":"Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human papilloma virus associated primary vaginal adenocarcinoma 人乳头状瘤病毒相关的原发性阴道腺癌
4区 医学 Q4 Medicine Pub Date : 2023-01-01 DOI: 10.22514/ejgo.2023.091
Primary vaginal adenocarcinoma associated with human papillomavirus (HPV) infection is extremely rare. We report a case of primary adenocarcinoma of the vagina associated with human papilloma virus successfully treated with anterior pelvic exenteration and adjuvant concurrent chemoradiation therapy. A 51-year-old postmenopausal woman (gravida 1, para 1) presented with intermittent vaginal bleeding and pelvic pain. She was found to have a 5 × 5 cm necrotic tumor took up the vaginal. She had no previous history of antenatal exposure to diethylstilbestrol (DES). Pelvic magnetic resonance imaging (MRI) demonstrated a 4.8 × 6.0 cm mass in the vaginal canal, an 1.1 × 2.6 cm mass at the urinary bladder dome and a 1.1 cm irregular lymph node at the right external iliac chain with increased fluorodeoxyglucose (FDG) uptake from Fused whole-body positron emission tomography-computed tomography (PET-CT). Based on clinical investigations, the patient was diagnosed with a primary adenocarcinoma of vagina, staged International Fedestration of Gynecology and Obstetrics (FIGO) IVa. Anterior pelvic exenteration, simple vulvectomy, total vaginectomy, both pelvic lymph node dissection, and para-aortic lymph node dissection with ileal conduit urinary diversion (Bricker’s operation) was done. Histologically primary vaginal HPV type 16-associated adenocarcinoma was confirmed. Both obturator lymph node was positive for metastasis. Postoperatively, the patient received weekly cisplatin regimen administered with a dose of 40 mg/m2 on day 1 of external radiation therapy (RT), 1 to 4 hours before RT initiation. External beam pelvic RT dose prescription to the whole pelvis was 59.4 Gy in 33 fractions at the isocenter. But, after total dose of 43.2 Gy, patient complained severe bowel habit change and discontinued further treatment. The patient remains free from recurrence 8 months after initial surgery. In the lack of information and comparative analysis of management options for the more unusual and rare varieties of primary vaginal neoplasms in the literature, this suggests the possibility that surgical treatment may be preferentially selected on a case-by-case basis.
原发性阴道腺癌与人乳头瘤病毒(HPV)感染是非常罕见的。我们报告一例原发性阴道腺癌伴人乳头瘤病毒成功治疗前盆腔切除和辅助同步放化疗。51岁绝经后妇女(妊娠1期,第1段)表现为间歇性阴道出血和盆腔疼痛。她被发现有一个5 × 5厘米的坏死肿瘤占据了阴道。她以前没有产前暴露于己烯雌酚(DES)的历史。盆腔磁共振成像(MRI)显示阴道管4.8 × 6.0 cm肿块,膀胱丘1.1 × 2.6 cm肿块,右侧髂外链1.1 cm不规则淋巴结,融合全身正电子发射断层扫描-计算机断层扫描(PET-CT)显示氟脱氧葡萄糖(FDG)摄取增加。经临床调查,患者确诊为原发性阴道腺癌,经国际妇产科学联合会(FIGO) IVa分级。行盆腔前清扫术、单纯外阴切除术、全阴道切除术、双盆腔淋巴结清扫术、主动脉旁淋巴结清扫术并回肠输尿管分流术(Bricker手术)。组织学证实原发阴道HPV 16型相关腺癌。双闭孔淋巴结转移阳性。术后,患者接受每周一次的顺铂方案,剂量为40mg /m2,于第1天外放射治疗(RT)开始前1至4小时。全骨盆外束放疗剂量处方为59.4 Gy,在等中心处分为33个分量。但是,在总剂量43.2 Gy后,患者抱怨严重的排便习惯改变并停止进一步治疗。患者术后8个月无复发。由于文献中缺乏对更罕见的原发阴道肿瘤的治疗方案的信息和比较分析,这表明可能会根据具体情况优先选择手术治疗。
{"title":"Human papilloma virus associated primary vaginal adenocarcinoma","authors":"","doi":"10.22514/ejgo.2023.091","DOIUrl":"https://doi.org/10.22514/ejgo.2023.091","url":null,"abstract":"Primary vaginal adenocarcinoma associated with human papillomavirus (HPV) infection is extremely rare. We report a case of primary adenocarcinoma of the vagina associated with human papilloma virus successfully treated with anterior pelvic exenteration and adjuvant concurrent chemoradiation therapy. A 51-year-old postmenopausal woman (gravida 1, para 1) presented with intermittent vaginal bleeding and pelvic pain. She was found to have a 5 × 5 cm necrotic tumor took up the vaginal. She had no previous history of antenatal exposure to diethylstilbestrol (DES). Pelvic magnetic resonance imaging (MRI) demonstrated a 4.8 × 6.0 cm mass in the vaginal canal, an 1.1 × 2.6 cm mass at the urinary bladder dome and a 1.1 cm irregular lymph node at the right external iliac chain with increased fluorodeoxyglucose (FDG) uptake from Fused whole-body positron emission tomography-computed tomography (PET-CT). Based on clinical investigations, the patient was diagnosed with a primary adenocarcinoma of vagina, staged International Fedestration of Gynecology and Obstetrics (FIGO) IVa. Anterior pelvic exenteration, simple vulvectomy, total vaginectomy, both pelvic lymph node dissection, and para-aortic lymph node dissection with ileal conduit urinary diversion (Bricker’s operation) was done. Histologically primary vaginal HPV type 16-associated adenocarcinoma was confirmed. Both obturator lymph node was positive for metastasis. Postoperatively, the patient received weekly cisplatin regimen administered with a dose of 40 mg/m2 on day 1 of external radiation therapy (RT), 1 to 4 hours before RT initiation. External beam pelvic RT dose prescription to the whole pelvis was 59.4 Gy in 33 fractions at the isocenter. But, after total dose of 43.2 Gy, patient complained severe bowel habit change and discontinued further treatment. The patient remains free from recurrence 8 months after initial surgery. In the lack of information and comparative analysis of management options for the more unusual and rare varieties of primary vaginal neoplasms in the literature, this suggests the possibility that surgical treatment may be preferentially selected on a case-by-case basis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of gynaecological oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1